Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) vs GeneDx Holdings Corp (WGS) Price & Performance

Vanguard Global ex-US Real Estate Index Fd ETFTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Vanguard Global ex-US Real Estate Index Fd ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.16 (market cap $3.80B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Vanguard Global ex-US Real Estate Index Fd ETF is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days and GeneDx Holdings Corp for 19 Days on average.

VNQIWGS
Market Cap
$3.80B$2.02B
Volume
277,049734,640
52-Week High
$50.76$167.51
52-Week Low
$41.81$34.51
Typical Hold Time
95 Days19 Days
Sector
—Health
Enterprise Value
—$2.05B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Global ex-US Real Estate Index Fd ETF

VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $42.08, up 0.63% with bearish technical signals from moving averages. The ETF provides international real estate exposure across 30+ countries, offering a higher dividend yield than domestic alternatives. Recent news highlights a significant 45.9% drop in short interest in September 2026, while technical indicators show oversold conditions with RSI readings below 30.

The ETF faces headwinds from global real estate market volatility but offers diversification benefits and income potential. Key risks include international currency exposure and regional economic uncertainties. The substantial decline in short interest suggests potential sentiment improvement, though technical trends remain bearish near-term.

GeneDx Holdings Corp

GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.

The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

VNQI
100% Buy0% Sell
Avg holding period · 95 Days
WGS
100% Buy0% Sell
Avg holding period · 19 Days

About Vanguard Global ex-US Real Estate Index Fd ETF

The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).

Read more on VNQI →

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS →